How Amgen Uses AI & Data Science to Revolutionize Marketing and Biotech Innovation

Knowledge at Wharton

Ask about Knowledge at Wharton

Episode Description

ABOUT THE EPISODE Sean Bruich, Senior Vice President of AI, Engineering and Data Science at Amgen, joins Barbara Kahn and Dr. Americus Reed, II to discuss how AI’s rapid evolution is transforming industries—not by replacing humans, but by creating new opportunities that blend human expertise with advanced technology to drive innovation and efficiency.

ABOUT THE PODCAST Marketing Matters is hosted by Wharton marketing professors Barbara Kahn and Americus Reed. Each week they discuss marketing and advertising trends, consumer behavior, data and analytics, the latest in retail marketing, brand-building, and much more with their expert guests. Episodes are recorded at the Wharton School.

#AIMarketing #MarketingInnovation #MarketingAnalytics #AIAdoption #Amgen #Biotech ----- The Wharton School of the University of Pennsylvania is committed to sharing its intellectual capital through Knowledge at Wharton, the school’s online business analysis journal.

Launched in 1999, Knowledge at Wharton offers free access to:

- Articles, podcasts, and videos highlighting Wharton faculty research and analysis of current business trends - Interviews with book authors from Wharton School Press - In-depth series of curated content like Wharton Executive Education’s Nano Tools for Leaders - A searchable database of more than 10,000 articles covering all aspects of business - A weekly newsletter that delivers Knowledge at Wharton insights directly to your inbox

Visit the Knowledge at Wharton homepage: https://whr.tn/3qUpSBE Subscribe to the Knowledge at Wharton YouTube channel: https://whr.tn/3DEAgAU

Read the full transcriptHide the full transcript
  1. Hello and welcome. You're listening to Marketing Matters on the Wharton Podcast Network, our weekly podcast where we
  2. analyze the latest in advertising, marketing, customer behavior, new product launches, retailing, and
  3. pharmaceuticals. Uh, I'm Barbara Khan, the Patty and JH Baker Professor of Marketing, and I'm joined by my co-host,
  4. Americus Reed, the Whitney M. Young Jr. Professor of Marketing and the brand identity theorist. Hello, Americus.
  5. >> Hi, Barbara. So, uh, this is the first week of classes. It's an incredible sort
  6. of energy on the campus. I'm loving it. Uh, one of the things we talked about today is level setting.
  7. >> I just mentioned it's your first week of classes. I've been teaching seven weeks.
  8. >> Seven weeks in. So, you're like, listen, I may be I'm into it now. America, you're brighteyed and bushy tail, but
  9. hey, it's going to catch up with you. >> We're all on midterms. I don't know where you are.
  10. >> I'm introducing the syllabus. And so, yeah. No, it's it's it's fascinating that you mentioned that because you know
  11. all of the things that are going on campus. One of the things I talked about today, Barbara, is we're talking about
  12. marketing and people think marketing is just advertising, but I was trying to explain to my class marketing is about
  13. strategy. And in fact, marketing actually starts with science and ends with art. And so I'm very fascinated by
  14. this interface of data science, artificial intelligence as a new technology that is making its way into
  15. marketing strategy, various ways that it's happening and all of these different interfaces. And so have you
  16. got anything for me today that can help illuminate this and further allow me to make the case to my students that
  17. there's a lot going on under the hood with respect to marketing strategy? Oh, well actually we have a very interesting
  18. guest today who can talk about a lot of those things because he's have a long and varied career. I'd like to introduce
  19. Shawn Buick who's currently the senior vice president of artificial intelligence and data at Amgen which is
  20. a pharmaceutical or biotech or anyway health kind of related company but he has a long history starting out at
  21. Stanford as a psychology and biological science major all the way through Google
  22. and Facebook and Nike. So he's kind of been at the right place at the right time. Anyway, welcome Sean to our show.
  23. >> Thank you, Americas. Thank you, Barbara. It's so great to be here. >> So, let's build on on Americas's um
  24. quest or introduction in some sense or question and just quickly go through your background because you do have a
  25. knack of being in the right place at the right time starting well Stanford wasn't
  26. the right place. You should have been a Wharton, but okay. >> Had to get that plug in. Very, very well
  27. done, Barbara. But then uh I think you went first to Google then to Facebook then to Nike and now to Amgen just as
  28. each one of those areas was doing some pretty interesting area connecting marketing with data science and now what
  29. I really like to talk about is what you're doing at Amgen. But let's start with your history.
  30. >> Sure. Yeah. I got my start uh up at Stanford and um I was working in a neuroiming lab. So this was right around
  31. the time you know this these new brain scanners were be being able to gaze into the working human mind functional
  32. magnetic resonance imaging. Um and and there were kind of two things that happened there. I think the first was
  33. you know this new technology allowed us to for the first time answer some questions that for 70 years in cognitive
  34. science weren't really answerable. And so I became really convinced up until that point I'd been you know studying
  35. the science but I became convinced that technology was going to be really important in understanding the world.
  36. And then the second thing was I had to learn how to code because this these data sets were so much bigger than the
  37. reaction time and wet lab and um you know survey data that sort of everybody was using at the time. And so that's
  38. what really got me started um in in my career and I I got a job at Google right at the beginnings of what you would now
  39. call consumer data science. >> Um had had just a a you know wonderful set of mentors there as we were um sort
  40. of exploring what was possible with this field. I went to Facebook and helped them launch the the ads business um
  41. where I led the the measurement science team, the data science team on the on the ads business. And then I spent the
  42. last 10 years at Nike where um I helped them with their direct to consumer digital transformation leading their
  43. data science and analytics and customer insights teams there. But as you said, I
  44. made a big uh switch about a year ago. So now I met I'm at Amgen which um if if folks don't know is one of the world's
  45. leading biotechnology companies. It makes medicines um for things like uh cancer and inflammatory disease and
  46. cardiovascular disease and rare disease. Um it's been around for for over 40 years. It was sort of one of the
  47. pioneering companies in the biotech revolution of the 1980s. Um, and my job here is to try to figure out how we can
  48. use AI and data uh to make better medicines for for patients. >> So, let me just build a little on this.
  49. Now, you've been there a year and um I mean I know you were what that health what did you say bio health or
  50. biological science undergrad major but that's not like major health credentials. So, but obviously they saw
  51. some advantage in what you did do for the last 10, 20 years. Uh, but how have you like learned about what Amgen does
  52. and h how did how did you get up to speed? How did you do that? >> Yeah. And and it's been a long time
  53. since I took my last biology class at at Stan Smith. >> Yeah. And I mean, the science here is is
  54. really complex. you know, it's genetics, it's it's biology, it's pharmarmacology.
  55. Um, and so it has been definitely a a a big ramp to to learn all about what we do at Amgen. And and you know, it is
  56. pretty different than online ads or shoes in a few in a few ways. I mean, I think the first is just the fact we're,
  57. you know, making medicines for for patients, which creates this incredibly high standard around reliability and
  58. safety and compliance and scientific accuracy. Um, but it is a scientific discovery, especially in in this space.
  59. Um, you know, where you're trying to take this molecule and turn it into a a medicine. It it uses really large data
  60. sets. It's actually surprisingly quantitative for me. I mean, there's definitely beers and labs and
  61. experiments, but it's also very quantitative. Um, and and it's increasingly relying on technology
  62. because the data sets are huge and these, you know, new artificial intelligence and machine learning
  63. algorithms we think um has has the potential to really change um sort of how we bring these these medicines to
  64. patients. So, so some of it is definitely new and and hard and and a ramp, but some of it feels, you know,
  65. much more comfortable, the the core first principles of data science or or the um, you know, underlying technology
  66. stack and the partners and things like that. >> So, if everybody is using AI, then is
  67. how do you differentiate? I mean, it seems like if you have AI, everybody's doing the same thing. Then how how does
  68. that work? No, you you bring up a great point, Barbara, and and I do think there's a lot of convergence now on how
  69. well these algorithms perform, you know, so in the old days, um you know, when I
  70. was getting my start as a as a data scientist, you know, your your magic sauce was very much like how good your
  71. your algorithm was, how good your model was. Um nowadays I think I think companies should be thinking about two
  72. things and and certainly we are here at at Amgen but I think if you look across uh you know my work work previously
  73. there was it was the same concepts you know the first is you the underlying data that you have as a company is is a
  74. pretty interesting differentiator and and I'm super excited about some of the data we have here at Amjen you know
  75. genetics data a long history of designing proteins um and molecules and and all those scientific experiments
  76. along the way that there's that you know that that set of data uh is is a really
  77. interesting differentiator >> and then I think increasingly what you're seeing is that there is an art
  78. and a science because you mentioned kind of the art and the science um of how do
  79. you implement these algorithms in a way that you know is impactful in a way that
  80. gets to scale quickly >> um and and realizes whatever impact you're trying to drive at at your
  81. company. And I think in both spots, there's going to be differences in how successful companies are. And so, um, I
  82. think I think that's kind of one of the most important and underappreciated parts of of how to win here.
  83. >> I love that point, Sean. One of the things that I talked to my class Sean is the idea of adoption of AI technologies
  84. and the statement that you made which is how do you make the company strategy infused deeply with the DNA of AI that
  85. seems not necessarily easy because you have different folks maybe even if it's a large company and you know aside from
  86. just having a bunch of young people who are sort of born into it in your company
  87. how do you go about creating that the right organizational culture and atmosphere
  88. where the adoption of these technologies and understanding of how to use and deploy them appropriately and well
  89. differentiated like Barbara said, how do you make that happen? What are the what
  90. are the things that you do to create the cohesiveness inside the building to be able to adopt that kind of culture?
  91. >> Yeah. I mean, this is a podcast, right? So, we have to have some controversy.
  92. Can I bring up the MIT AI paper because it Yes. Definitely a controversial topic
  93. and I think one that's worth digging into a little bit because I think it it strikes right at the heart of of kind of
  94. your question. Okay. So for if >> if people are not tracking, there was a a paper by MIT that came out uh probably
  95. four weeks ago that you know the headlines have all said 95% of AI pilots in companies don't generate value. Um
  96. now that's the headline. The real story I think is is is twofold. So the first story is that if you're in a big company
  97. and you do a pilot, it never generates scale business value. That's the whole point of a pilot, right? Is it's little.
  98. Um now there's a muscle around how do you choose the right pilots? because pilots are only valuable if they teach
  99. you something you didn't know or derisk an investment by by you know trying it out in a specific zone or or sometimes I
  100. think what you as you mentioned you know shines a light on a success story that can absolutely inspire and teach your
  101. your colleagues and your workforce a path forward but lots of pilots lots of sort of poorly thought through poorly
  102. targeted random pilots is not a measure of success. And there's a lot of companies, I think, doing way too many
  103. pilots that are kind of not ever going to generate real value because then you have to have the practice and the and
  104. the skill set and the technology stack and the monitoring capabilities to take the winners and get them scaled and
  105. adopted and and that I think is a is is a real lesson um from this paper. Now, now why did these 95% of these programs
  106. in this paper fail? This isn't always in the headline. It wasn't the AI technology. It wasn't like
  107. the algorithms were crappy. It wasn't that the that the AI failed. It was everything else about it. There wasn't
  108. alignment on the budget. Business processes weren't evolved. There wasn't receptivity on the part of the people
  109. using it. They didn't get adoption. And and so that speaks exactly to your point, which is even if you have an
  110. amazing capability, if if you don't get everybody else lined up around it in a big company, you're never going to get
  111. the the business value out of it. And I think that's another piece that companies are struggling with is is how
  112. do you line up everything such that you can really pull these through to value um and and make an impact on the on on
  113. whatever mission you're trying to accomplish. >> Well, so how do you do it? No, it I I think it's this there's
  114. there's three pieces. I think you have to have the discipline around where are you going to do the pilots and what are
  115. they designed to teach you? And you know, here at Amgen, we have a we have a very rigorous process. It it's not
  116. anybody can run any pilot anywhere around AI. We're we're directing those pilots at specific zones that are going
  117. to teach us something. You have to have this muscle around how do you take a great pilot and and get it
  118. to scale. So and and and you know that's a technical question around you know do
  119. you have the right data infrastructure do you have the right um technology portfolio do the right monitoring uh
  120. programs to get these algorithms implemented and then there's all of the change management stuff that you know is
  121. not all that different than every other technology transformation that you guys have studied you know that we've looked
  122. at digital marketing you know 15 years ago direct to consumer you know 10 years ago So um but if but if you don't have
  123. all three of those I think it's really hard to make a big impact and and you know one or two of them isn't enough.
  124. >> So let me let me just summarize that. So like the first one is kind of how to ask
  125. the right questions right where to focus is the first thing and then and you can
  126. ask a lot of wrong questions but understanding where you're focusing is basically what you're saying and I could
  127. totally see how that'll differ from firm to firm to firm. So it wouldn't result in the same thing. And then once you get
  128. viable ideas, implementing and and bringing to and operationalizing and then scaling is a whole other issue. And
  129. then the third one is getting the organization around this new is that it >> Yeah, I think that's a great a great
  130. summary. It's it's you know the discipline around pilots, where you play, how you test ideas, how you turn
  131. the Yeah. turn turn the big ones the the best into impactful scale programs and then how do you line up all of the
  132. pieces that are necessary to to make to make the impact through those through those uh scale pilots for sure. So it
  133. seems like how to do it right would suggest that there's like some measurement system or some objectives
  134. you and some like metrics that you have along the way in order to see if you're making prog is that kind of the way it
  135. goes or how do you know you're on the right track? Yeah, I look I think there are um you know a whole host of
  136. technical things we do to make sure these models are performing well and you know having thoughtful evaluation
  137. frameworks and um you know looking at their performance and um all of that stuff is is sort of the job of the data
  138. science team or the AI team. But I think you know the the bigger question goes back to that conversation we were just
  139. having around is it actually making an impact on your strategy. You know is it is it driving whatever outcomes you as a
  140. business are trying to are you trying to trying to enact. And that I think is the
  141. place where sometimes you know the plot gets a little bit lost. you focus too much on the technical implementations or
  142. the technology roadmap or the or you know the path that the that all the um the data and the algorithms and the
  143. technology stack need to be um all right and and sometimes you lose track of the
  144. the organizational and business partnership. I mean we understand what you're saying Sean which is like the the
  145. specific role of the technology needs to be managed in a way that is built around
  146. the synchronization of its adoption within the organization and how to in your case how to figure out the bi the
  147. specific biology that produces new opportunities for wellness products or health related uh protocols and things
  148. of that nature. So we definitely understand that it's just challenging because and whenever I hear a talk Sean
  149. on AI and you're a guru of this I sit back and I have to like suspend a lot of my judgment because I just don't know
  150. what you're talking about in terms of the technical pieces of it. You know all of these s sort of things. I understand
  151. the logic of it but I want to know much more to Barbara's point about you know how does this work? What is a what's an
  152. example of a specific pilot? if you could share that, you know, things that we've that you guys have done. Maybe
  153. that's the secret sauce and you can't talk about it, but like taking us through like here's something we did
  154. that's, you know, more public information now and here's an example of how we really brought in AI to really
  155. help us drive a specific understanding of a biological element that then turned into something that we could quickly
  156. scale and create something that adds value to the marketplace. Is there an example you could share with us?
  157. >> Sure. Yeah. I mean I think what is exciting and you know part of why I wanted to come to Amgen is I really do
  158. think biotechnology is is a spot where um some of the biggest advances in AI and data science are going to happen
  159. over the course of the next few years. I mean I I am so excited about what's possible and there's been some big
  160. breakthroughs and you know just last October um the winner of the Nobel Prize in
  161. chemistry was shared between the Google deep mic guys Dennis and a professor at the University of Washington David
  162. Baker. And you know what that that breakthrough um was was an algorithm called alphafold which was solving this
  163. like incredibly complicated uh problem in science which is how do you predict the way po proteins fold if
  164. you know the >> the the two-dimensional sort of structure of the protein can you predict
  165. the three-dimension structure and that >> interesting >> you know fortunately that actually
  166. happened after I joined Amgen because it attracted a whole bunch of news to the fact that AI and data science had had a
  167. potential potentially, you know, a big impact on on this field. But since I had joined a few months earlier, it looked
  168. like I was super smart and my timing was perfect as opposed to uh joining joining
  169. after the the news coverage. But that's an example, I think, of a big breakthrough. And, you know, there are
  170. relatively few of those along the way. M >> um you know I think the the more common
  171. instantiation of like an incredible impact of a of a data science uh project is actually just much more simple. So
  172. let me give you one. >> Okay. >> I did not know any of this a year and a half ago but but it turns out to be a
  173. good medicine the the molecules have to be a certain very narrow range of viscosity. M
  174. >> so like imagine >> you have a molecule it works pretty well but it's like peanut butter like too
  175. thick >> you can't inject that into the human body it's not going to work and so one
  176. of the most important criteria our scientists have to consider when they're designing these molecules is like how
  177. viscous is the solution of these of these proteins after after we uh engineer them and you know even that
  178. developing a a machine learning algorithm >> takes into account all the historical
  179. experiments >> got it >> and makes a prediction as to whether these molecules are going to be in the
  180. right zone to be a medicine >> can dramatically improve the efficiency of our scientists. So you know they
  181. don't have to make a hundred of these molecules and then see how viscous they are. they can use this algorithm and it
  182. dramatically cuts may not it may not be right all the time but it at least improves the efficiency of those
  183. scientists lets them direct their energy their creativity their time against a higher um fidelity of candidate right a
  184. small smaller pool more likely to be successful so you know those are the type of like blocking and tackling yeah
  185. incremental work >> that you know before we had access to all of that data being digitized and
  186. before our algorithms were powerful enough to make strong predictions, you couldn't couldn't reduce that workload.
  187. You couldn't shape shape where they're spending their time and attention. >> Interesting.
  188. >> That's the type of stuff just across the board we're looking at of how do you you
  189. know add a little bit of data science into the day of a protein engineer or a biologist or a geneticist um or a
  190. process engineer um you know a supply chain expert, right? And and and just incrementally move the needle on how
  191. efficient and effective they can be. So Sean, one of the things I'm interested in as you're telling us the critical
  192. role that AI does play and how it can really make things better. One of the things people are really afraid of is AI
  193. replacing other, you know, people working at a company. But the way you're describing it, it doesn't sound like
  194. that to me, and I wonder if you agree with it. It actually sounds like there's more room for people who know how to use
  195. AI and are trained to use AI and it might even provide more jobs than less. I almost got that impression from what
  196. you're saying, but I don't know if you want to go so far as to say something like that.
  197. >> Yeah, I'm no economist, so I won't weigh in on on maybe the um the economics of
  198. it, but I'm I'm thinking about it in in two ways. I think as we're implementing AI systems today, that human AI
  199. interface is actually critically important. And so, you know, we call it human in the loop. that's kind of the
  200. the term folks folks are using, but particularly when it pertains to like scientific inquiry and ensuring quality
  201. and compliance and adhering to like, you know, the incredibly high standards of of scientific accuracy that we have to
  202. adhere to. Having a human inside that system engaging with the technology and the AI algorithms themselves and the
  203. output is is critically important. And I I don't see that changing anytime soon.
  204. >> The other thing is as we as we build these systems, >> there's a whole set of new roles that
  205. are being created >> that exist on on this edge. I mean, look, just just to zoom in on my career,
  206. I have never had a job >> in which there had been a prior incumbent in that job over the last 25
  207. years. about you, but >> yeah, >> I don't want to overextend from an N of one, Barbara, but I I think everyone
  208. would agree that's dangerous in in science and marketing. >> But I do think it speaks to this is an
  209. exciting time. I mean when I look at my whole career and and know I've been around data science since the really
  210. early days this is the single most interesting exciting moment that I've seen in that time. I think the
  211. capabilities you know the combination of computing power and data that's that's been digitized and available um and the
  212. performance of these of these new models is is really transformational. I think,
  213. you know, tools like chat GPT are are just incredible. I'm sure many of your listeners are are big users of it.
  214. >> Yeah, I'm sure they use it all the time. >> And then, you know, I really do think
  215. one of the biggest challenges in data science over the last 20 25 years has been just it's been really restricted to
  216. people who are really highskilled like you know they know we know Python, know how to use the technology, work at a
  217. company that has big data sets. But the other thing that's really fun here is is
  218. this has really democratized the power of data and algorithms in a way that almost everybody out there listening can
  219. probably find, you know, a handful of spots even just in their own lives, whether it's making shopping lists or
  220. planning vacations or automating workflows, you know, getting work done faster. That's going to have a pretty
  221. big impact. So, I'm I'm really excited about, you know, the positive impacts that that these new technologies are
  222. going to have on on us at work and us outside of work. Yeah, Sean, this is uh super intriguing to me. I I want to, you
  223. know, ask this question because I think it's important when we have the gurus available to us to put them into the
  224. time machine and give us some insight into their crystal ball about what is the state of the world in your domain,
  225. artificial intelligence, uh data science, all of these things. Um what is that going to look like in your view
  226. five to 10 years from now? Well, I am too good of a data scientist to get busted by making predictions too
  227. far into the future. So, I'm gonna I'm gonna tell you what I think now and then maybe gaze just a little bit more
  228. approximately into the future. But um you know, look, I think the biggest mistake people make in a moment like
  229. this around a big technological uh revolution, evolution of of data science and algorithms and data is that they
  230. over focus on the here and now. the failures of of technologies, the hype cycles that turn out to be, you know,
  231. overheated and they underestimate in the medium term how pervasive and impactful
  232. some of these technologies can be. And I I think that's the big disconnect I see
  233. right now between kind of the here and now. you know, we've all had a moment where the algorithm didn't do what we
  234. wanted it to do or there's not enough data to make the prediction or, you know, chatbt gives you a lousy answer.
  235. And and those things are true. Um, but I I do think in the medium term, folks are
  236. underestimating how big of an impact uh this this new set of capabilities is going to have. And that's a big part of
  237. why I came to Amjen is I'm I'm really bullish on what I think is is possible here. Now, you got to do all the stuff
  238. we talked about to to actually make the impact at at scale. Um, but I I think uh
  239. this is a really exciting space to watch and folks should folks should lean in and watch it.
  240. >> Well, Sean, thank you so much for joining us today. It's always a pleasure to have you. And um where can our
  241. listeners go to to keep up with what you're doing? Do you have a website or or public facing side of Amgen so people
  242. can figure out, you know, how amaning into AI? Yeah, definitely. If you're interested in either the science or the
  243. AI of what we've talked about today, check out amjen.com. There's a bunch of great stories and teams there keep
  244. everybody up to date on what we're working on. >> Okay. Well, that's great. Thank you very
  245. much. And that's all we have time for today. We'd like to thank our producers, Aaron TR and Marissa Rena. And thank you
  246. all for listening. We'll be back next week. Till then, this has been Marketing Matters on the Wharton Podcast Network.
  247. I'm Barbara Khan here with America's Reed. [Music]

Brief Summary

Shawn Buick discusses AI's impact on marketing and pharmaceuticals, emphasizing efficiency and the importance of organizational culture in technology adoption.

Key points

  • The Essence of Marketing. Americus Reed explains that marketing is more than just advertising; it's about strategy and science.
  • The Role of Technology in Science. Shawn Buick emphasizes the importance of technology in understanding complex scientific questions.
  • Transforming Biotechnology with AI. Shawn Buick shares insights on how AI can revolutionize medicine development at Amgen.
  • AI Adoption Challenges. Shawn Buick discusses the difficulties of integrating AI into company strategy and culture.
  • AI Pilot Failures. A striking statistic reveals that 95% of AI pilots fail to deliver value in companies.
  • AI and Job Creation. Exploring the potential for AI to create more jobs rather than eliminate them.

Episode highlights

Tension

45/ 100Some tension

Related episodes